PULMATRIX, INC. Operating Lease, Weighted Average Discount Rate, Percent
PULMATRIX, INC. (PULM) had Operating Lease, Weighted Average Discount Rate, Percent of 11.00% as of 2024-03-31, per its 10-Q filed 2024-05-10.
Financial Statements › Notes › Leases
us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent · last filed 2025-03-21
- 2024-03-31: Operating Lease, Weighted Average Discount Rate, Percent 11.00%.
- 2023-12-31: Operating Lease, Weighted Average Discount Rate, Percent 11.00%.
- 2023-09-30: Operating Lease, Weighted Average Discount Rate, Percent 11.00%.
- 2023-06-30: Operating Lease, Weighted Average Discount Rate, Percent 8.40%.
| Period end | Operating Lease, Weighted Average Discount Rate, Percent |
|---|---|
| 2024-03-31 | 11.00% 10-Q · filed 2024-05-10 |
| 2023-12-31 | 11.00% 10-K · filed 2025-03-21 |
| 2023-09-30 | 11.00% 10-Q · filed 2024-11-08 |
| 2023-06-30 | 8.40% 10-Q · filed 2024-08-13 |
| 2023-03-31 | 8.40% 10-Q · filed 2024-05-10 |
| 2022-12-31 | 2.97% 10-K · filed 2024-03-28 |
| 2022-09-30 | 3.00% 10-Q · filed 2022-11-10 |
| 2022-06-30 | 3.00% 10-Q · filed 2022-08-10 |
| 2022-03-31 | 2.97% 10-Q · filed 2022-05-12 |
| 2021-12-31 | 2.97% 10-K · filed 2023-03-30 |
| 2020-12-31 | 5.23% 10-K · filed 2022-03-29 |
| 2020-09-30 | 5.23% 10-Q · filed 2020-11-12 |
| 2020-06-30 | 5.23% 10-Q · filed 2020-08-07 |
| 2019-12-31 | 7.44% 10-K · filed 2021-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |